# OnCo record paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026" ;
  schema:name "Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial"@en ;
  schema:alternateName "inMIND"@en, "Sehn 2026"@en ;
  schema:description "Adding a third antibody, directed at a different target, to the usual tablet-and-antibody pairing added about eight months before follicular lymphoma progressed again."@en ;
  schema:url <https://onco.cc/key-papers/paper-inmind-tafasitamab-lenalidomide-rituximab-follicular-lancet-2026/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(25)01778-7>, <https://pubmed.ncbi.nlm.nih.gov/41360064/>, <https://europepmc.org/article/MED/41360064> ;
  onco:tag "lymphoma-evidence" ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(25)01778-7> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Sehn LH, Hübel K, Luminari S, et al." ;
  onco:related <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd20/> ;
  onco:drugs <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/rituximab/> ;
  onco:companies <https://onco.cc/companies/incyte/> ;
  onco:trials <https://onco.cc/trials/nct04680052/> ;
  onco:people <https://onco.cc/people/laurie-sehn/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-combination-space/>, <https://onco.cc/bottlenecks/b-resistance/> ;
  onco:journals <https://onco.cc/journals/lancet/> .